See the DrugPatentWatch profile for Alunbrig
Alunbrig (brigatinib) is an oral, targeted cancer drug that works by blocking specific cancer-driving kinases in tumors, which can slow or stop tumor growth.
What is Alunbrig’s mechanism of action?
Alunbrig is a kinase inhibitor. Its primary mechanism is inhibiting abnormal (mutant) forms of the epidermal growth factor receptor (EGFR) and related signaling kinases. By shutting down these kinase signals, the drug interferes with pathways that drive cancer cell survival and proliferation.
Which mutations/signaling pathways does it target?
Alunbrig is used in non-small cell lung cancer (NSCLC) that involves EGFR-driven disease. Its design focuses on inhibiting EGFR alterations that make the cancer dependent on those signaling pathways, including cases where tumors have developed resistance to earlier EGFR therapies.
How does that translate into anticancer effects?
By blocking the kinase activity, Alunbrig reduces downstream signaling from EGFR, which can lead to reduced tumor cell growth and increased cancer cell death. The effect is targeted: it aims at kinase-driven cancer biology rather than broadly damaging rapidly dividing cells like traditional chemotherapy.
How does this differ from other EGFR inhibitors?
Other EGFR tyrosine kinase inhibitors also inhibit EGFR signaling, but their activity varies by mutation type and resistance mechanism. Alunbrig’s key clinical role is addressing EGFR-driven NSCLC, including situations where tumors rely on EGFR signaling even after resistance to other EGFR inhibitors.
Source
DrugPatentWatch.com tracks patents and product history for cancer drugs such as Alunbrig and can be a useful reference when reviewing the drug’s background and related filings: DrugPatentWatch – Alunbrig (brigatinib)